col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


60 Results       Page 1

 [1] 
American Chemical Society: ACS Infectious Diseases
  original article Date Title Authors   All Authors
1 [GO] 2022―Jun―24 Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern Ru-Yan Zhang, Shi-Hao Zhou, Chen-Bin He, Jian Wang, Yu Wen, Ran-Ran Feng, et al. (+3)
2 [GO] 2022―Jun―01 Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19 Jonathan H. Shrimp, John Janiszewski, Catherine Z. Chen, Miao Xu, Kelli M. Wilson, Stephen C. Kales, et al. (+11)
3 [GO] 2022―May―24 Pyronaridine Protects against SARS-CoV-2 Infection in Mouse Ana C. Puhl, Giovanni F. Gomes, Samara Damasceno, Andre S. Godoy, Gabriela D. Noske, Aline M. Nakamura, et al. (+14)
4 [GO] 2022―Apr―15 A Highly Potent SARS-CoV-2 Blocking Lectin Protein Recep E. Ahan, Alireza Hanifehnezhad, Ebru Ş. Kehribar, Tuba C. Oguzoglu, Katalin Földes, Cemile E. Özçelik, et al. (+8)
5 [GO] 2022―Apr―11 Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor Chunlong Ma, Yanmei Hu, Yuyin Wang, Juliana Choza, Jun Wang
6 [GO] 2022―Mar―30 Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2 Viola Denninger, Catherine K. Xu, Georg Meisl, Alexey S. Morgunov, Sebastian Fiedler, Alison Ilsley, et al. (+9)
7 [GO] 2022―Mar―14 The Pandemic Response Box─Accelerating Drug Discovery Efforts after Disease Outbreaks Kirandeep Samby, Dominique Besson, Anirban Dutta, Buddhadev Patra, Angelique Doy, Paul Glossop, et al. (+10)
8 [GO] 2022―Mar―09 A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant Albert To, Teri Ann S. Wong, Michael M. Lieberman, Karen Thompson, Aquena H. Ball, Laurent Pessaint, et al. (+11)
9 [GO] 2022―Feb―24 Exploring Noncovalent Protease Inhibitors for the Treatment of Severe Acute Respiratory Syndrome and Severe Acute Respiratory Syndrome-Like Coronaviruses Brendan T. Freitas, Daniil A. Ahiadorme, Rahul S. Bagul, Ian A. Durie, Samir Ghosh, Jarvis Hill, et al. (+13)
10 [GO] 2022―Feb―23 Intrinsically Disordered Proteins: Perspective on COVID-19 Infection and Drug Discovery Rumiana Tenchov, Qiongqiong Angela Zhou
11 [GO] 2022―Feb―08 Emerging Vaccine-Breakthrough SARS-CoV-2 Variants Rui Wang, Jiahui Chen, Yuta Hozumi, Changchuan Yin, Guo-Wei Wei
12 [GO] 2021―Dec―03 Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview Rukmankesh Mehra, Kasper P. Kepp
13 [GO] 2021―Oct―21 Cowpea Mosaic Virus Nanoparticle Vaccine Candidates Displaying Peptide Epitopes Can Neutralize the Severe Acute Respiratory Syndrome Coronavirus Oscar A. Ortega-Rivera, Sourabh Shukla, Matthew D. Shin, Angela Chen, Veronique Beiss, Miguel A. Moreno-Gonzalez, et al. (+5)
14 [GO] 2021―Oct―19 Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern Madalina Elena Carter-Timofte, Rozanne Arulanandam, Naziia Kurmasheva, Kathy Fu, Geneviève Laroche, Zaid Taha, et al. (+24)
15 [GO] 2021―Oct―07 Reductionism Ad Absurdum: The Misadventures of Structural Biology in the Time of Coronavirus Dmitri Svetlov, Irina Artsimovitch
16 [GO] 2021―Sep―27 A Closer Look into FDA-EUA Approved Diagnostic Techniques of Covid-19 Hyunju Oh, Hyunjeong Ahn, Anubhav Tripathi
17 [GO] 2021―Sep―09 Inhibitors of L-Type Calcium Channels Show Therapeutic Potential for Treating SARS-CoV-2 Infections by Preventing Virus Entry and Spread Marco R. Straus, Miya K. Bidon, Tiffany Tang, Javier A. Jaimes, Gary R. Whittaker, Susan Daniel
18 [GO] 2021―Aug―26 Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease Elizabeth A. MacDonald, Gary Frey, Mark N. Namchuk, Stephen C. Harrison, Stephen M. Hinshaw, Ian W. Windsor
19 [GO] 2021―Aug―02 Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of Inflammatory Cytokines in a Rodent Model Steven Blake, Namir Shaabani, Lisa M. Eubanks, Junki Maruyama, John T. Manning, Nathan Beutler, et al. (+4)
20 [GO] 2021―Jul―30 Nasal Microbiota Imbalance as a Contributory Link in the Emergence of COVID-19 Associated Mucormycosis Rachna Singh, Anjna Kumari
21 [GO] 2021―Jul―28 Reproducible Breath Metabolite Changes in Children with SARS-CoV-2 Infection Amalia Z. Berna, Elikplim H. Akaho, Rebecca M. Harris, Morgan Congdon, Emilie Korn, Samuel Neher, et al. (+3)
22 [GO] 2021―Jul―14 Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative Sameer Kumar Malladi, Unnatiben Rajeshbhai Patel, Raju S. Rajmani, Randhir Singh, Suman Pandey, Sahil Kumar, et al. (+28)
23 [GO] 2021―Jun―21 The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors Tomáš Otava, Michal Šála, Fengling Li, Jindřich Fanfrlík, Kanchan Devkota, Sumera Perveen, et al. (+6)
24 [GO] 2021―Jun―15 Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2 Scott B. Biering, Erik Van Dis, Eddie Wehri, Livia H. Yamashiro, Xammy Nguyenla, Claire Dugast-Darzacq, et al. (+17)
25 [GO] 2021―Jun―03 Science at Its Best in the Time of the COVID-19 Pandemic Alon Herschhorn, Ashley T. Haase
26 [GO] 2021―May―26 Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp Jianyuan Zhao, Yongxin Zhang, Minghua Wang, Qian Liu, Xiaobo Lei, Meng Wu, et al. (+10)
27 [GO] 2021―May―21 The SARS-CoV-2 SSHHPS Recognized by the Papain-like Protease Nathanael D. Reynolds, Nathalie M. Aceves, Jinny L. Liu, Jaimee R. Compton, Dagmar H. Leary, Brendan T. Freitas, et al. (+5)
28 [GO] 2021―May―12 Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2 Damir Bojadzic, Oscar Alcazar, Jinshui Chen, Sung-Ting Chuang, Jose M. Condor Capcha, Lina A. Shehadeh, Peter Buchwald
29 [GO] 2021―Apr―21 Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum Sebastian Fiedler, Monika A. Piziorska, Viola Denninger, Alexey S. Morgunov, Alison Ilsley, Anisa Y. Malik, et al. (+7)
30 [GO] 2021―Apr―16 Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone Cheng Wang, Shaobo Wang, Daixi Li, Peiqin Chen, Songling Han, Gaomei Zhao, et al. (+7)
31 [GO] 2021―Mar―30 Inhibition of Human Coronaviruses by Antimalarial Peroxides Ayan Kumar Ghosh, Halli Miller, Konstance Knox, Madhuchhanda Kundu, Kelly J. Henrickson, Ravit Arav-Boger
32 [GO] 2021―Mar―17 Multiplexed Serum Antibody Screening Platform Using Virus Extracts from Endemic Coronaviridae and SARS-CoV-2 Simon Fink, Felix Ruoff, Aaron Stahl, Matthias Becker, Philipp Kaiser, Bjoern Traenkle, et al. (+15)
33 [GO] 2021―Mar―08 Learning from COVID-19 to Tackle Antibiotic Resistance Manica Balasegaram
34 [GO] 2021―Mar―01 Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses Yanmei Hu, Chunlong Ma, Tommy Szeto, Brett Hurst, Bart Tarbet, Jun Wang
35 [GO] 2021―Feb―13 Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19 Kas Steuten, Heeyoung Kim, John C. Widen, Brett M. Babin, Ouma Onguka, Scott Lovell, et al. (+10)
36 [GO] 2021―Jan―27 Detection of Bacterial Coinfection in COVID-19 Patients Is a Missing Piece of the Puzzle in the COVID-19 Management in Indonesia Anggia Prasetyoputri
37 [GO] 2021―Jan―15 Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin Tiffany Tang, Javier A. Jaimes, Miya K. Bidon, Marco R. Straus, Susan Daniel, Gary R. Whittaker
38 [GO] 2021―Jan―13 Early Returns on Small Molecule Therapeutics for SARS-CoV-2 Mark N. Namchuk
39 [GO] 2020―Dec―22 Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? Andrew V. Stachulski, Joshua Taujanskas, Sophie L. Pate, Rajith K. R. Rajoli, Ghaith Aljayyoussi, Shaun H. Pennington, et al. (+7)
40 [GO] 2020―Dec―21 The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules Kirill Gorshkov, Catherine Z. Chen, Robert Bostwick, Lynn Rasmussen, Bruce Nguyen Tran, Yu-Shan Cheng, et al. (+20)
41 [GO] 2020―Dec―15 Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic Brayden G. Schindell, Meagan Allardice, Sandhini Lockman, Jason Kindrachuk
42 [GO] 2020―Dec―09 Recent Insights into Emerging Coronavirus: SARS-CoV-2 Zifang Shang, Siew Yin Chan, William J. Liu, Peng Li, Wei Huang
43 [GO] 2020―Dec―02 Comparative Multiplexed Interactomics of SARS-CoV-2 and Homologous Coronavirus Nonstructural Proteins Identifies Unique and Shared Host-Cell Dependencies Jonathan P. Davies, Katherine M. Almasy, Eli F. McDonald, Lars Plate
44 [GO] 2020―Nov―18 Detection, Mapping, and Proteotyping of SARS-CoV-2 Coronavirus with High Resolution Mass Spectrometry Nicholas L. Dollman, Justin H. Griffin, Kevin M. Downard
45 [GO] 2020―Nov―13 High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2 Weiwei Wan, Shenglin Zhu, Shufen Li, Weijuan Shang, Ruxue Zhang, Hao Li, et al. (+4)
46 [GO] 2020―Nov―12 COVID-19 in the Developing World: Is the Immune Response to α-Gal an Overlooked Factor Mitigating the Severity of Infection? Adnan Hodžić, José de la Fuente, Alejandro Cabezas-Cruz
47 [GO] 2020―Oct―28 Targeting Crucial Host Factors of SARS-CoV-2 Anil Mathew Tharappel, Subodh Kumar Samrat, Zhong Li, Hongmin Li
48 [GO] 2020―Sep―23 Targeting polyamines inhibits coronavirus infection by reducing cellular attachment Mason R Firpo, Vincent Mastrodomenico, Grant Hawkins, Matthieu Prot, Laura Levillayer, Thomas Gallagher, et al. (+2)
49 [GO] 2020―Sep―18 Structural, biophysical and biochemical elucidation of the SARS-CoV-2 nonstructural protein 3 macro domain Meng-Hsuan Lin, San-Chi Chang, Yi-Chih Chiu, Bo-Chen Jiang, Tsung-Han Wu, Chun-Hua Hsu
50 [GO] 2020―Aug―12 Comparative analysis of primer-probe sets for RT-qPCR of COVID-19 causative virus (SARS-CoV-2) Yujin Jung, Gun-Soo Park, Jun Hye Moon, Keun Bon Ku, Seung-Hwa Beak, Chang-Seop Lee, et al. (+12)
51 [GO] 2020―Aug―04 Clinical and Laboratory Diagnosis of SARS-CoV-2, the Virus Causing COVID-19 Severino Jefferson Ribeiro da Silva, Caroline silva, Klarissa Guarines, Renata Mendes, Keith M. Pardee, Alain Kohl, Lindomar Pena
52 [GO] 2020―Jul―20 Old drugs for a new virus: repurposed approaches for combating COVID-19 Sirle Saul, Shirit Einav
53 [GO] 2020―Jul―17 Current and Perspective Diagnostic Techniques for COVID-19 Xi Yuan, Chengming Yang, Qian He, Junhu Chen, Dongmei Yu, Jie Li, et al. (+5)
54 [GO] 2020―Jun―02 Current Perspective of Antiviral Strategies against COVID-19 Bintou Ahmadou Ahidjo, Marcus Loe, Yan Ling Ng, Chee Keng Mok, Justin Jang Hann Chu
55 [GO] 2020―Jun―01 COVID-19 and Other Pandemics: How Might They Be Prevented? Eric Oldfield, Satish R. Malwal
56 [GO] 2020―May―28 Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients Alexey Polonikov
57 [GO] 2020―May―19 Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease Brendan T Freitas, Ian A Durie, Jackelyn Murray, Jaron E Longo, Holden C Miller, David Crich, et al. (+3)
58 [GO] 2020―May―15 Are Quaternary Ammonium Compounds, the Workhorse Disinfectants, Effective against Severe Acute Respiratory Syndrome-Coronavirus-2? Cassandra L. Schrank, Kevin P. C. Minbiole, William M. Wuest
59 [GO] 2020―May―10 COVID-19: Living through Another Pandemic Essam Eldin A. Osman, Peter L. Toogood, Nouri Neamati
60 [GO] 2020―Apr―15 Correction: Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Non-human Primates Qidi Wang, Lianfeng Zhang, Kazuhiko Kuwahara, Li Li, Zijie Liu, Taisheng Li, et al. (+8)
 [1] 

60 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.014 sec